Healthcare AI Platform Comparison: Clinical Safety First

Healthcare AI sits under specific regulation and affects patient care. This guide covers evaluating it, drawing on FISTA Solutions' AI enablement governance work. This is general guidance, not medical or legal advice.

What must be established?

Six requirements, in this order.

Requirement	What to establish	Why it comes here
Regulatory classification	Device status in your jurisdiction	Determines everything else
Clinical validation	Evidence on similar populations	Performance may not transfer
Clinical decision boundary	Written and enforced	Patient safety
Patient data handling	Lawful basis and controls	Tightly regulated
Workflow integration	Fits clinical practice	Adoption
Audit trail	Every interaction recorded	Review and challenge

Why does classification come first?

Because it determines what applies.

Whether a product is regulated as a medical device in your jurisdiction governs the evidence required, the approvals needed, and the obligations you take on by deploying it. Classification varies by jurisdiction and by intended use.

This is a question for regulatory and legal specialists, not for a procurement checklist. Establish it before anything else. This is general guidance, not medical or legal advice.

What validation evidence transfers?

Evidence from populations resembling yours.

Performance measured on one population may not hold on another with different demographics, comorbidity patterns, or care pathways. The study population should be described and compared against yours.

Ask for study design, endpoints, and population characteristics, and have clinical colleagues assess whether the evidence applies to your setting. See AI bias testing checklist.

Where is the clinical boundary?

At any decision affecting patient care.

AI may surface relevant history, summarise a record, flag a possible interaction, or prioritise a worklist. The diagnosis, the treatment decision, and the accountability for both remain with the clinician.

Write that boundary down and design the workflow so it is enforced rather than assumed. Alert fatigue and volume pressure both erode it otherwise. See why human oversight is a design problem.

What data constraints apply?

Substantial ones, varying by jurisdiction.

Patient data carries specific rules on processing, transfer across borders, retention, and consent. Where the platform processes data, which subprocessors are involved, and what is retained all need clear answers.

Establish the position with counsel before any patient data reaches the platform. This is general guidance, not medical or legal advice. See AI data map template.

Why does workflow fit decide adoption?

Because clinicians have no spare time.

A tool requiring a separate system, extra clicks, or work outside the clinical record will not be used regardless of its accuracy. Integration into the existing workflow is what determines whether it delivers anything.

Assess this with clinicians in a real setting rather than in a demonstration. See the end of generic chatbots.

What is the lower-risk starting point?

Documentation and administrative assistance.

Drafting clinical notes from a consultation, summarising a long record, and supporting coding all save clinician time with a clinician reviewing everything and no clinical decision automated.

Those deliver measurable benefit with a substantially lower regulatory and safety burden than decision support. See document AI platform comparison.

How do you run your own comparison?

Establish classification with specialists, then have clinicians assess validation evidence against your population and test the tool in a real workflow.

Measure time saved and error rate with clinicians scoring outputs. Both are necessary; neither is sufficient alone.

What does switching cost later?

Low technically. The cost is clinical process change, retraining, and any regulatory documentation tied to a specific product.

Keep patient records and audit trails in your own systems.

What do people get wrong here?

Classification assumed. Validation evidence from a different population. Clinical boundary undocumented. Data position settled internally. And deployment without clinician involvement in the workflow design.

What governance applies ongoing?

Monitoring of performance in your setting, incident reporting, and periodic revalidation — not just approval at deployment.

Performance can drift as populations and practice change, and detecting that requires ongoing measurement with clinical involvement. See AI quarterly review checklist.

Which should you choose?

Establish regulatory classification before anything else, require validation evidence on comparable populations, and keep clinical decisions with clinicians. Start with documentation assistance, which delivers benefit at a substantially lower burden.

What should you do first?

Establish with specialists whether the product is a regulated device in your jurisdiction. Everything else depends on that answer.

How FISTA Solutions helps

FISTA Solutions builds and operates production AI systems through AI agents, AI enablement, and forward deployed engineering: regulatory classification and validation evidence established before deployment, with clinical decisions kept with clinicians and performance monitored in the client's own setting, decisions documented with their reasoning, and handover that leaves your team able to maintain what was delivered. The record is 150+ projects for 50+ companies across 12+ countries.

To run this comparison against your own workload, message FISTA on WhatsApp, or read AI bias testing checklist.